|
Osteoporosis
References
American Association of Clinical Endocrinologists. Osteoporosis Guidelines. Updated 2003. Available at: http://www.aace.com/pub/pdf/guidelines/osteoporosis2001Revised.pdf. Accessed: Oct 2007.
American Academy of Orthopedic Surgeons. AAOS On-Line Service- Osteoporosis. Reviewed 2000. Available at: http://orthoinfo.aaos.org/brochure/thr_report.cfm?Thread_ID=13&topcategory=Osteoporosis&searentry=osteoporosis. Accessed: October 2007.
Amizuka N, Shimomura J, Li M, et al. Defective bone remodelling [sic] in osteoprotegerin-deficient mice. Journal of Electron Microscopy (Tokyo). 2003;52(6):503-513.
Ammann P. Strontium ranelate: A novel mode of action leading to renewed bone quality. Osteoporosis International. Published online ahead of print. December 2, 2004.
Anderson HC. An antagonist of osteoclast integrins prevents experimental osteoporosis [editorial]. Journal of Clinical Investigation. 1997;99(9):2059.
Ansbacher R, Carson DS, Lourwood DL, et al. Pharmacist's guide to managing menopause. Amherst, NJ: Center for Pharmaceutical Care at Amherst. 1995.
Ansbacher R, Carson DS, Lourwood DL, et al. Pharmacist's guide to managing menopause. Amherst, NJ: Center for Pharmaceutical Care at Amherst. 1995.
Bezerra FF, Laboissiere FP, King JC, Donangelo CM. Pregnancy and lactation affect markers of calcium and bone metabolism differently in adolescent and adult women with low calcium intakes. Journal of Nutrition. 2002;132(8):2183-2187.
Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clinical Endocrinology (Oxford). 2004;60(5):568-575.
Biskobing DM. Novel therapies for osteoporosis. Expert Opinion on Investigational Drugs. 2003;12(4):611-621.
Boyce BF, Xing L, Shakespeare W, Wang Y, Dalgarno D, Iuliucci J, Sawyer T. Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kidney International. 2003;(85 Suppl):S2-S5.
Burgaud JL, Riffaud JP, Del Soldato P. Nitric-oxide releasing molecules: a new class of drugs with several major indications. Current Pharmaceutical Design. 2002;8(3):201-213.
Canalis MD E. Growth hormone, skeletal growth factors and osteoporosis. Endocrine Practice. 1995;1(1):39-43.
Carbone LD, Tylavsky FA, Cauley JA, et al. Association between bone mineral density and the use of nonsteroidal [sic] anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. Journal of Bone and Mineral Research. 2003;18(10):1795-1802.
Celiker R, Arslan S. Comparison of serum insulin-like growth factor-1 and growth hormone levels in osteoporotic and non-osteoporotic postmenopausal women. Rheumatology International. 2000;19(6):205-208.
Colon-Emeric CS, Caminis J, Suh TT, et al; HORIZON Recurrent Fracture Trial. The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Current Medical Research and Opinion. 2004;20(6):903-910.
Colorado Health Site Home page. Osteoporosis. No date given. Available at: http://www.coloradohealthsite.org/osteo/osteo_main.html. Accessed: August 2003.
Cruz AC, Gruber BL. Statins and osteoporosis: can these lipid-lowering drugs also bolster bones? Cleveland Clinic Journal of Medicine. 2002;69(4):277-278, 280-282, and 287-288.
Cushenberry LM, de Bittner MR. Potential use of HMG-CoA reductase inhibitors for osteoporosis. Annals of Pharmacotherapy. 2002;36(4):671-678.
Delmas PD. Clinical effects of strontium ranelate in women with postmenopausal osteoporosis. Osteoporosis International. Published online ahead of print. December 2, 2004.
Devogelaer JP. A review of the effects of tibolone on the skeleton. Expert Opinion on Pharmacotherapy. 2004;5(4):941-949.
Dickman PW, Adolfsson J, Astrom K, Steineck G. Hip fractures in men with prostate cancer treated with orchiectomy. Journal of Urology. 2004;172(6, Part 1 of 2):2208-2212.
Dodds RA. A cytochemical assay for osteoclast cathepsin K activity. Cell Biochemistry and Function. 2003;21(3):231-234.
Doggrell SA. Present and future pharmacotherapy for osteoporosis. Drugs Today (Barcelona). 2003;39(8):633-657.
Doggrell SA. Recent important clinical trials of drugs in osteoporosis. Expert Opinion on Pharmacotherapy. 2004;5(7):1635-1638.
Dresner-Pollak R, Rosenblatt M. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis. Journal of Cellular Biochemistry. 1994;56(3):323-330.
e-Medicine. Osteoporosis. Exams and tests. No date given. Available at: http://www.emedicinehealth.com/articles/5516-5.asp. Accessed October 2007.
Engleman VW, Nickols GA, Ross FP, et al. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. Journal of Clinical Investigation. 1997;99(9):2284-2292.
Ensom MH, Liu PY, Stephenson MD. Effect of pregnancy on bone mineral density in healthy women. Obstetrical and Gynecological Survey. 2002;57(2):99-111.
Evista [package insert]. Indianapolis, IN: Eli Lilly and Company; July, 2002.
Falchetti A. Genetics of osteoarticular disorders, Florence, Italy, 22-23 February 2002. Arthritis Research. 2002;4(5):326-331.
Fleisch H. Bisphosphonates in osteoporosis. European Spine Journal. 2003;12(Suppl 2):S142-S146.
FORTEO [package insert]. Indianapolis, IN: Eli Lilly and Company; September, 2004.
Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, Genazzani AR. A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women. Gynecology and Endocrinology. 2004;18(1):9-16.
Gamero P, Sornay-Rendu E, Delmas PD. Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet. 2000;355(9207):898-899.
Garrett IR, Gutierrez G, Mundy GR. Statins and bone formation. Current Pharmaceutical Des. 2001;7(8):715-736.
Gennari C. Analgesic effect of calcitonin in osteoporosis. Bone. 2002;30(5 Suppl):67S-70S.
Geusens P, Hochberg MC, van der Voort DJ, et al. Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clinic Proceedings. 2002;77(7):629-637.
Grigorie D, Neacsu E, Marinescu M, Popa O. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. Romanian Journal of Internal Medicine. 2003;41(4):409-415.
Haguenauer D, Welch V, Shea B, Tugwell P, Wells G. Fluoride for treating postmenopausal osteoporosis. Cochrane Database Systematic Review. 2000;(4):CD002825.
Helen Hays Hospital and the State of New York. Osteoporosis risk assessment for men. November 2003. Available at: http://www.health.state.ny.us/nysdoh/osteo/men.htm. Accessed October 2007.
Holmes SJ, Shalet SM. Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Hormone Research. 1996;45(1-2):86-93.
Horton MA. Integrin antagonists as inhibitors of bone resorption: implications for treatment. Proceedings of the Nutrition Society. 2001;60(2):275-281.
International Osteoporosis Foundation. Available at: http://www.osteofound.org/ Accessed: October 2007.
James IE, Lark MW, Zembryki D, et al. Development and characterization of a human in vitro resorption assay: demonstration of utility using novel antiresorptive agents. Journal of Bone and Mineral Research. 1999 Sep;14(9):1562-1569.
Javaid MK, Godfrey KM, Taylor P, Shore SR, Breier B, Arden NK, Cooper C. Umbilical venous IGF-1 concentration, neonatal bone mass, and body composition. Journal of Bone and Mineral Research. 2004;19(1):56-63.
Jehle S, Zanetti A, Muser J, Hulter HN, and Krapf R. Partial neutralization of the acidogenic western diet with potassium citrate increases bone mass in postmenopausal women with osteopenia. J Am Soc Nephrol. Oct 2006.
Kalkwarf HJ, Specker BL. Bone mineral changes during pregnancy and lactation. Endocrine. 2002;17(1):49-53.
Kawahara TN, Krueger DC, Engelke JA, Harke JM, Binkley NC. Short-term vitamin A supplementation does not affect bone turnover in men. Journal of Nutrition. 2002;132(6):1169-1172.
Keeble JE, Moore PK. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. British Journal of Pharmacology. 2002;137(3):295-310.
Kelley GA et al. Efficacy of resistance exercise on lumbar spine and femoral neck bone mineral density in premenopausal women: a meta-analysis of individual patient data. Journal of Women?s Health. 2004. 13:293-300.
Khan AN, Macdonald S. Osteoporosis, involutional. E-Medicine. Last Updated October 4, 2004. Available at: http://www.emedicine.com/radio/topic503.htm. Accessed October 2007.
Klein BY, Tepper SH, Gal I, Shlomai Z, Ben-Bassat H. Opposing effects of tyrosine kinase inhibitors on mineralization of normal and tumor bone cells. Journal of Cellular Biochemistry. 1997;65(3):420-429.
Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas. 2004;489Suppl 10:S30-S40.
Kurabayashi T, Matsushita H, Kato N, et al. Effect of vitamin D receptor and estrogen receptor gene polymorphism on the relationship between dietary calcium and bone mineral density in Japanese women. Journal of Bone and Mineral Metabolism. 2004;22(2):139-147.
Lark MW, Stroup GB, Hwang SM, et al. Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis. Journal of Pharmacology and Experimental Therapeutics. 1999;291(2):612-617.
LeBoff MS et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999; 281:1505-1511.
Lim LS, Harnack LJ, Lazovich D, Folsom AR. Vitamin A intake and the risk of hip fracture in postmenopausal women: the Iowa Women's Health Study. Osteoporosis International. 2004;15(7):552-559.
Liu YZ, Liu YJ, Recker RR, Deng HW. Molecular studies of identification of genes for osteoporosis: the 2002 update. Journal of Endocrinology. 2003;177(2):147-196.
Long JR, Zhang YY, Liu PY, et al. Association of estrogen receptor alpha and vitamin D receptor gene polymorphisms with bone mineral density in Chinese males. Calcified Tissue International. 2004;74(3):270-276.
Lourwood DL. Hormone replacement therapy. In Carter B, Angaran D, Sisca T (eds.) Pharmacotherapy self-assessment program: Module 5. Nephrology, endocrinology, and immunology. Kansas City: American College of Clinical Pharmacy 1993:189-202, 216-19 (Book A), and 41-46 (Book B).
Marie PJ. Strontium ranelate: a novel mode of action optimizing bone formation and resorption. Osteoporosis International. Published online ahead of print. December 2, 2004.
Mayo Clinic Home Page. Osteoporosis. Available at: http://www.mayoclinic.com/health/osteoporosis/DS00128/DSECTION=1. Accessed: Oct 2007.
Mayo Clinic Home Page. The latest on hormone replacement therapy. Available at: http://www.mayoclinic.com/invoke.cfm?objectid=1F105F0E-73F3-4004-9EAECABBF2BCB7FA. No date given. Accessed: August 2003.
Medscape Medical News. Osteoporosis Guidelines Updated. Available at URL: http://www.medscape.com/viewarticle/533846. Accessed: October 2007.
Mehta NM, Malootian A, Gilligan JP. Calcitonin for osteoporosis and bone pain. Current Pharmaceutical Design. 2003;9(32):2659-2676.
Mercer B, Markland F, Minkin C. Contortrostatin, a homodimeric snake venom disintegrin, is a potent inhibitor of osteoclast attachment. Journal of Bone and Mineral Research. 1998;13(3):409-414.
Metcalf CA 3rd, van Schravendijk MR, Dalgarno DC, Sawyer TK. Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Current Pharmaceutical Design. 2002;8(23):2049-2075.
Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New England Journal of Medicine. 2004;350(5):459-468.
Michaelssan K, Lithell H. Serum retinol levels and the risk of fracture. New England Journal of Medicine. 2003; 4(348):287-294.
Miller WH, Keenan RM, Willette RN, Lark MW. Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor). Drug Discovery Today. 2000;5(9):397-408.
Miyauchi A, Notoya K, Taketomi S, et al. Novel ipriflavone receptors coupled to calcium influx regulate osteoclast differentiation and function. Endocrinology. 1996;137(8):3544-3550.
Mousa SA. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Current Opinion in Chemistry and Biology. 2002;6(4):534-541.
National Institute of Arthritis and Musculoskeletal and Skin Disease home page. http://www.niams.nih.gov/hi/topics/osteoporosis/opbkgr.htm. Accessed: August 2003.
National Institutes of Health. Osteoporosis and Related Bone Diseases. Osteoporosis overview. Revised November 2006. Available at http://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/default.asp. Accessed: October 2007.
National Osteoporosis Foundation home page. Available at:http://www.nof.org/. Accessed: Oct 2007.
National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass. No date given. Highlights available at: http://www.nof.org/advocacy/prevalence/. Accessed November 16, 2004.
National Osteoporosis Foundation. Medications to prevent and treat osteoporosis. No date given. Available at: http://www.nof.org/patientinfo/medications.htm. Accessed October 2007.
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. Journal of the American Medical Association. 2001;285:785-795.
Office of the Surgeon General. Bone health and osteoporosis: a report of the Surgeon General. Rockville, Md.: Department of Health and Human Services, 2004.
Osteoporosis and Related Bone Diseases National Resource Center. National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health. What is bone? Revised August 2005. Available at: http://www.niams.nih.gov/Health_Info/Bone/Bone_Health/default.asp. Accessed: October 2005.
Oursler MJ, Spelsberg TC. Echistatin, a potential new drug for osteoporosis. Endocrinology. 1993;132(3):939-940.
Prelevic GM, Markou A, Arnold A, Bartram C, Puzigaca Z, Ginsburg J. The effect of tibolone on bone mineral density in postmenopausal women with osteopenia or osteoporosis--8 years follow-up. Maturitas. 2004;47(3):229-234.
Promislow JH, Hertz-Picciotto I, Schramm M, Watt-Morse M, Anderson JJ. Bed rest and other determinants of bone loss during pregnancy. American Journal of Obstetrics and Gynecology. 2004;191(4):1077-1083.
Ralston SH. Genetic control of susceptibility to osteoporosis. Journal of Clinical Endocrinology and Metabolism. 2002;87(6):2460-2466.Recker RR, Deng HW. Role of genetics in osteoporosis. Endocrine. 2002;17(1):55-66.
Reginster JY, Lecart MP, Deroisy R, Lousberg C. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Expert Opinion on Investigational Drugs. 2004;13(7):857-864.
Riera-Espinoza G, Ramos J, Carvajal R, et al. Changes in bone turnover during tibolone treatment. Maturitas. 2004;47(2):83-90.
Ringa V. Alternatives to hormone replacement therapy for menopause: an epidemiological evaluation. [Article in French] Journal of Gynecology, Obstetrics and Biological Reproduction (Paris). 2004;33(3):195-209.
Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Current Molecular Medicine. 2002;2(6):571-577.
Rosen CJ, Bilezikian JP. Clinical review 123: Anabolic therapy for osteoporosis. Journal of Clinical Endocrinology and Metabolism. 2001;86(3):957-964.
Rosen Clifford J M.D. Postmenopausal Osteoprosis. The New England Journal of Medicine. August 11, 2005. 323(6):595-603.
Rubin MR, Bilezikian JP. New anabolic therapies in osteoporosis. Endocrinology and Metabolism Clinics of North America. 2003;32(1):285-307.
Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric. 2002;5(4):390-398.
Schlienger RG, Meier CR. HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture? Drugs and Aging. 2003;20(5):321-336.
Schweiger U, Deuschle M, Korner A, et al. Low lumbar bone mineral density in patients with major depression. American Journal of Psychiatry. 1994;151(11):1691-1693.
Setchell KD, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. American Journal of Clinical Nutrition. 2003;78(3 Suppl):593S-609S.
Shakespeare WC, Metcalf CA 3rd, Wang Y, et al. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. Current Opinion in Drug Discovery and Development. 2003;6(5):729-741.
Solomon DH, Finkelstein JS, Wang PS, Avorn J. Statin lipid-lowering drugs and bone mineral density. Pharmacoepidemiology and Drug Safety. 2004 Jul 20.
Standing Committee on the Scientific Evaluation of Dietary Reference Intakes (DRI Committee) of the Food and Nutrition Board, Institute of Medicine, National Academy of Sciences, and Health Canada. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. December 1, 1997. Available at: http://www.nap.edu/books/0309063507/html/index.html. Accessed October 2007.
Susva M, Missbach M, Green J. Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Trends in Pharmacological Sciences. 2000;21(12):489-495.
Swegle JM, Kelly MW. Tibolone: a unique version of hormone replacement therapy. Annals of Pharmacotherapy. 2004;38(5):874-881.
Tas N, Aricioglu A, Erbas D, Ozcan S. The effect of calcitonin treatment on plasma nitric oxide levels in post-menopausal osteoporotic patients. Cell Biochemistry and Function. 2002;20(2):103-105.
Tiegs RD, Body JJ, Wahner HW, Barta J, Riggs BL, Heath H 3rd. Calcitonin secretion in postmenopausal osteoporosis. New England Journal of Medicine. 1985;312(17):1097-1100.
University of Florida. Continuing Medical Education. Post-Menopausal Osteoporosis: Key Issues. January 1997. Available at: http://cme.ufl.edu/media/osteo/ Accessed: October 2007.
U.S. Department of Agriculture. Agricultural Research Service. USDA Database for Standard Reference. Release 17. Calcium, Ca (mg) content of selected common foods, sorted by nutrient content. 2004. Available at: http://www.nal.usda.gov/fnic/foodcomp/Data/SR17/wtrank/sr17w301.pdf Accessed October 2007.
U.S. Food and Drug Administration. FDA Talk Paper. FDA approves teriparatide to treat osteoporosis. November 6, 2002. Available at: http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01176.html. Accessed: October 2007.
Ueland T. Bone metabolism in relation to alterations in systemic growth hormone. Growth Hormone and IGF Research. 2004;14(6):404-417.
van't Hof RJ, Ralston SH. Nitric oxide and bone. Immunology. 2001;103(3):255-261.
Violette SM, Shakespeare WC, Bartlett C, et al. A Src SH2 selective binding compound inhibits osteoclast-mediated resorption. Chemistry and Biology. 2000;7(3):225-235.
WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. Geneva, Switzerland: World Health Organization; 1994.
|
References
